SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Exclusion Criteria

• •2. Subjects who suffer from cardiovascular diseases of clinical significance.
• •3. Subjects with serious and/or uncontrolled concomitant diseases.
• •4. Subjects diagnosed active hepatitis B or hepatitis C.
• •5. Subjects have known human immunodeficiency virus (HIV) infection that is not well controlled.
• •6. Subjects with known active tuberculosis.
• •7. Known allergy or hypersensitivity to pembrolizumab or SKB264, or the excipients of pembrolizumab or SKB264.
• •8. Subjects with history of allogeneic tissue/solid organ transplant.
• •9. Subjects previously treated with TROP2 targeted therapy.
• •10. Subjects who are vaccinated with live vaccine within 30 days before the first dose, or plan to be vaccinated with live vaccine during the study period.
• •11. Subjects participating in another clinical study, unless it is an observational (non-intervention) clinical study or the follow-up period of an intervention study.
• •12. The Investigator considers other situations that will interfere with the evaluation of the study intervention or the safety of the subjects or the interpretation of the results of the study.